Call us : 855-228-7355

Investor Relations

Agent Benefits 4

Novus Q3 2024: A Strong Quarter Amidst Industry Shifts

A New Frontier: Cannabis Coverage in Health Plans

Click Below For 

2024 Review and 2025 Outlook

The Latest:

$NDEV stands out with these key factors driving its recent momentum:

*UPDATE-Federal Legislation: SAFE Banking Act and efforts for Rescheduling, have bipartisan support. Some Republican senators believe there are enough votes to pass it. It will only take four Republican senators, alongside Democrats, are needed for it to succeed, and our assessment indicates that there are many more supporters in the Senate.

*Federal Research Being Funded: Federal agencies, such as Veterans Affairs, and the FDA (Food and Drug Administration) are allocating funds for further research, and an increasing number of banks are starting to engage in business within the cannabis sector.

*Sustaining Business Model: In the unlikely event the Rescheduling or SAFER Banking Act is not enacted, Novus can still sustain its business model without external funding. Our focus on generating revenue and profitability allows us to reinvest profits, maintain independence, and drive continuous innovation and market growth.

Quote and Research Links are Below

About Novus:

Since 2015, Novus Acquisition & Development Corporation (NDEV), d/b/a Novus Cannabis MedPlanⓇ, has been a pioneer in integrating THC and CBD cannabis into health insurance plans for both medical and recreational cannabis consumers. With over 1,200 agents, brokers, and dispensaries, NDEV generates revenue through insurance premiums and provides policyholders access to affordable treatment options. 

The company’s niche is offering cannabis as an alternative to opioids and protecting veterans from VA benefit denials due to participation in state-approved cannabis programs. NDEV’s sustainability is based on its receivable-based business model. It has attracted interest from major carriers and InsurTech platforms for future plan integration.

Cap Structure

As of June 1, 2024
Authorized Shares:200 million
Outstanding Shares:107,803,624
Float:30,948,730
Par Value:$0.001
Restricted Shares:76,854,894
Research With Your 
Adviser
  

Due Diligence Review

Quote: Click Here
Press Releases: Click Here
Filings: Click Here
Pitch Deck: Click Here
Investment Highlights Video: Click Here
Disclaimer and Forward-Looking Statement Click Here

Contact Us

* Indicates Required Field

855-228-7355

We are available Monday - Friday 9:00 am - 5:00 pm (EST) Email: info@getnovusnow.com

  • follow us on